Photolitec
East Amherst
About Photolitec
A spin-off of Roswell Park Cancer Institute (RPCI), Photolitec is a new life-sciences company developing photosensitizing compounds for image-guided photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI's Photodynamic Therapy Center. The compounds that Photolitec is working to commercialize were developed primarily by Ravindra Pandey, Ph.D. while at RPCI. Dr. Pandey is a Distinguished Member of the PDT Center and Director of Pharmaceutical Chemistry at RPCI, and is the founder and Chief Scientific Officer of Photolitec.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.6M
- Last round: Series Unknown (Mar 2015)
- Website: photolitec.org
- Phone: 716.845.4565
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/photolitec-2624512 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.